ES2180258T3 - Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes. - Google Patents

Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.

Info

Publication number
ES2180258T3
ES2180258T3 ES99401645T ES99401645T ES2180258T3 ES 2180258 T3 ES2180258 T3 ES 2180258T3 ES 99401645 T ES99401645 T ES 99401645T ES 99401645 T ES99401645 T ES 99401645T ES 2180258 T3 ES2180258 T3 ES 2180258T3
Authority
ES
Spain
Prior art keywords
expression
improve
adenoviral
open reading
genes expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES99401645T
Other languages
English (en)
Inventor
Majid Mehtali
Monika Lusky
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of ES2180258T3 publication Critical patent/ES2180258T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)

Abstract

Se describen vectores adenovirales recombinantes que retienen suficientes secuencias E4 para mejorar la expresión y/o persistencia de la expresión de un gen de interés. Además la invención describe el uso de un polinucleótido que codifica uno o más ORF(s) de la región E4 de un adenovirus seleccionado entre ORF1, ORF2, ORF3, ORF4, ORF3/4, ORF6/7, ORF6 Y ORF7 tomados individualmente o en combinación para mejorar la expresión y/o la persistencia de la expresión de un gen de interés operablemente unido a elementos reguladores e insertado dentro de un vector de expresión. Finalmente, se describen una célula anfitriona, una composición, una partícula viral infecciosa que comprende dicho polinucleótido o vector adenoviral, un procedimiento para preparar dicha partícula viral así como su uso terapéutico.
ES99401645T 1998-07-07 1999-07-01 Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes. Expired - Lifetime ES2180258T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401722 1998-07-07
EP98402825 1998-11-13

Publications (1)

Publication Number Publication Date
ES2180258T3 true ES2180258T3 (es) 2003-02-01

Family

ID=26151663

Family Applications (2)

Application Number Title Priority Date Filing Date
ES99401645T Expired - Lifetime ES2180258T3 (es) 1998-07-07 1999-07-01 Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
ES01124236T Expired - Lifetime ES2210081T3 (es) 1998-07-07 1999-07-01 Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01124236T Expired - Lifetime ES2210081T3 (es) 1998-07-07 1999-07-01 Utilizacion de los marcos de lectura de la region e4 para la mejora de la expresion de genes.

Country Status (11)

Country Link
US (1) US6475480B1 (es)
EP (2) EP1199368B1 (es)
JP (1) JP2000106875A (es)
AT (2) ATE258228T1 (es)
AU (1) AU756607B2 (es)
CA (1) CA2276791A1 (es)
DE (2) DE69903229T2 (es)
DK (2) DK1199368T3 (es)
ES (2) ES2180258T3 (es)
HK (1) HK1043390A1 (es)
PT (2) PT1199368E (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6225113B1 (en) * 1998-12-04 2001-05-01 Genvec, Inc. Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene in an at least E4-deficient adenovirus
EP1301612A2 (en) * 2000-05-31 2003-04-16 Genvec, Inc. Method and composition for targeting an adenoviral vector
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
AU2003268145A1 (en) * 2002-08-22 2004-03-11 Merck And Co., Inc. Methods for propagating adenovirus and virus produced thereby
DK1648931T3 (da) 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
CN101128593B (zh) * 2004-12-31 2014-09-03 佩尔·松内·霍尔姆 逆转动物细胞中多种抗性的方法
US20080166322A1 (en) * 2006-12-08 2008-07-10 Atkinson Richard L Methods for producing an adenovirus type 5 gene transfer vector
WO2008089448A2 (en) * 2007-01-19 2008-07-24 Cornell Presearch Foundation, Inc. Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis
EP2606137B1 (en) * 2010-08-16 2018-08-01 Salk Institute For Biological Studies Anti-cancer adenoviruses
KR101522341B1 (ko) * 2012-10-02 2015-05-21 국립암센터 신규한 조건부-복제 가능 아데노바이러스 및 그의 제조 방법
EP2912069B1 (en) 2012-10-23 2019-07-31 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
WO2018093932A2 (en) 2016-11-16 2018-05-24 Immunomic Therapeutics, Inc. Nucleic acids for treatment of allergies
CN110062630A (zh) 2016-12-12 2019-07-26 萨克生物研究学院 肿瘤靶向合成腺病毒及其用途
KR20240027895A (ko) 2017-05-02 2024-03-04 이뮤노믹 쎄라퓨틱스, 인크. 암 항원을 포함하는 lamp (리소솜 연관 막 단백질) 구축물
JP2021523185A (ja) 2018-05-15 2021-09-02 イミュノミック セラピューティックス， インコーポレイテッドＩｍｍｕｎｏｍｉｃ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． アレルゲンを含む改善されたｌａｍｐ構築物
CA3140019A1 (en) * 2019-05-30 2020-12-03 Gritstone Bio, Inc. Modified adenoviruses
CA3153850A1 (en) 2019-10-18 2021-04-22 Teri Heiland Improved lamp constructs comprising cancer antigens
CN110714027A (zh) * 2019-10-28 2020-01-21 嘉铭(固安)生物科技有限公司 一种表达质粒、用于包装二代腺病毒的细胞株及其应用
CN110656090B (zh) * 2019-10-28 2023-06-30 嘉兴安宇生物科技有限公司 一种表达质粒、用于包装容量增加的二代腺病毒的细胞株及其应用
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
WO2023201201A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructs comprising immune response enhancing genes and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670488A (en) * 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
CA2592997A1 (en) * 1992-12-03 1994-06-09 Genzyme Corporation Pseudo-adenovirus vectors
FR2726285B1 (fr) * 1994-10-28 1996-11-29 Centre Nat Rech Scient Adenovirus depourvus de particules contaminantes viables, preparation et utilisation
US5756283A (en) * 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
US6110744A (en) * 1996-11-13 2000-08-29 Board Of Regents, The University Of Texas System Diminishing viral gene expression by promoter replacement
US5981275A (en) * 1997-04-14 1999-11-09 Genzyme Corporation Transgene expression system for increased persistence
US6100086A (en) * 1997-04-14 2000-08-08 Genzyme Corporation Transgene expression systems

Also Published As

Publication number Publication date
AU3800999A (en) 2000-06-08
DK0974668T3 (da) 2002-11-11
EP1199368B1 (en) 2004-01-21
EP0974668B1 (en) 2002-10-02
US6475480B1 (en) 2002-11-05
EP1199368A3 (en) 2002-07-17
AU756607B2 (en) 2003-01-16
DE69903229T2 (de) 2003-06-26
ES2210081T3 (es) 2004-07-01
ATE258228T1 (de) 2004-02-15
EP1199368A2 (en) 2002-04-24
EP0974668A1 (en) 2000-01-26
DE69903229D1 (de) 2002-11-07
DK1199368T3 (da) 2004-04-13
DE69914382D1 (de) 2004-02-26
DE69914382T2 (de) 2004-11-04
PT1199368E (pt) 2004-04-30
CA2276791A1 (en) 2000-01-07
PT974668E (pt) 2003-01-31
JP2000106875A (ja) 2000-04-18
HK1043390A1 (zh) 2002-09-13
ATE225400T1 (de) 2002-10-15

Similar Documents

Publication Publication Date Title
ES2180258T3 (es) Utilizacion de pautas de lectura abierta adenovirales de e4 para mejorar la expresion de genes.
Colby et al. Adenovirus type 5 virions can be assembled in vivo in the absence of detectable polypeptide IX
IL234063A0 (en) Sequences of adenoid virus serological type 7 and recombinant viruses containing them
WO2000028061A3 (en) Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
WO2005001103A3 (en) Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses
HK1071518A1 (en) Improved raav expression systems for genetic modification of specific capsid proteins
IL174653A0 (en) Promoters for expression in modified vaccinia virus ankara
EP0851769A4 (en) GENE THERAPY WITH THE HELP OF SHEEP ADENOVIRAL VECTORS
NZ500540A (en) Purified proteins, fusion proteins, recombinant vector, vaccine, kit, comprising proteins from Actinobacillus pleuropneumoniae
GB0027088D0 (en) DNA expression vectors
WO2006116267A3 (en) Cell-specific molecule and method for importing dna into osteoblast nuclei
WO2005010149A3 (en) Subgroup b adenoviral vectors for treating disease
WO2001073028A3 (en) A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
EP1203819A3 (en) Anti-inflammatory vectors
EP0752888A4 (en) NUCLEOTID AMINO ACID SEQUENCES OF THE HERPEVIRUS gB, gC AND gD FROM DOG AND THEIR USE
EP1845163A3 (en) Adeno-associated virus serotype l nucleic acid sequences, vetors and host cells containing same
EP0774002A4 (en) DNA CODING FOR THE SHEEP ADENOVIRUS (OAV287) AND THEIR USE AS A VIRAL VECTOR
WO2006086357A3 (en) Adenovirus serotype 36 vectors, nucleic acid and viruses produced thereby
WO2001092495A3 (en) A human lysyl ixodase (47765) and uses thereof
WO1992014818A3 (en) Entomopoxvirus expression system comprising spheroidin or thymidine-kinase sequences
AU1281902A (en) Adenoviral vectors for gene delivery in skeletal muscle cells or myoblasts
WO2003031633A3 (de) Adenovirales vektorsystem
Agrawal et al. 800. Generation of Recombinant Skin In Vitro by Adeno-Associated Virus Type 2 Vector Transduction
WO2000043514A3 (en) Human acid sensing ion channel and uses thereof
JPH0773500B1 (es)